European Commission approves Merck Serono's Rebif in early MS
This article was originally published in Scrip
Executive Summary
The European Commission (EC) has approved an extended indication for Merck Serono's Rebif (interferon beta-1a), allowing its use in patients with early multiple sclerosis (MS), in line with an earlier recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).